Treatment of steroid refractory acute GvHD with AbGn-168H
LOS ALTOS, CA, USA I May 18, 2015 I AbGenomics International announced the start of a phase-Ib/IIa clinical trial using the lead compound Neihulizumab (AbGn-168H) to treat steroid refractory acute GvHD (aGvHD). This investigator-initiated trial is sponsored by Stanford University in its nation’s leading bone marrow transplant program. The primary objective of the study is to evaluate the safety and efficacy of AbGn-168H in patients with steroid refractory aGvHD in the post-allogeneic transplantation setting. aGVHD is a major complication of hematopoietic cell transplantation (HCT) that accounts for most non-relapse mortality and limits the use of HCT. Steroid refractory aGVHD carries an especially high mortality of between 60-85%. According to key opinion leaders in this field, a huge unmet medical need of aGvHD needs to be satisfied under the existing therapies.
Prior to the aGvHD trial, the proof of clinical efficacy and safety of AbGn-168H, a humanized monoclonal antibody, has been well demonstrated in a randomized, multicenter, double-blind, placebo-controlled phase II trial in patients with moderate-to-severe plaque psoriasis. Most recently, AbGenomics has also initiated an open-label, multi-center phase II study for psoriatic arthritis. The company is dedicated to bring forth this potential game-changing therapeutic candidate for the treatment of various inflammatory diseases.
About AbGenomics (www.abgenomics.com)
AbGenomics International Inc. (AbG) is an innovative, clinical-stage biopharmaceutical company developing targeted antibody therapeutics for the treatment of immune-mediated inflammatory diseases and cancers. Headquartered in San Francisco Bay Area, U.S., AbGenomics has subsidiaries in the Netherlands and in Taiwan. The lead candidate for anti-inflammatory therapy, Neihulizumab (AbGn-168H), is a therapeutic antibody with potential of long lasting drug-free remission and less risk concern for infections. In company’s oncology portfolio, the biosuperior antibody drug conjugate (ADC), featured on their superior efficacy and safety profiles, has proved to show a sustainable competitive advantage over our competitors. The Company’s strategy is to commercialize its novel products in collaboration with major pharmaceutical partners in order to maximize the opportunity for development and marketing of the Company’s compounds.
SOURCE: AbGenomics
Post Views: 36
Treatment of steroid refractory acute GvHD with AbGn-168H
LOS ALTOS, CA, USA I May 18, 2015 I AbGenomics International announced the start of a phase-Ib/IIa clinical trial using the lead compound Neihulizumab (AbGn-168H) to treat steroid refractory acute GvHD (aGvHD). This investigator-initiated trial is sponsored by Stanford University in its nation’s leading bone marrow transplant program. The primary objective of the study is to evaluate the safety and efficacy of AbGn-168H in patients with steroid refractory aGvHD in the post-allogeneic transplantation setting. aGVHD is a major complication of hematopoietic cell transplantation (HCT) that accounts for most non-relapse mortality and limits the use of HCT. Steroid refractory aGVHD carries an especially high mortality of between 60-85%. According to key opinion leaders in this field, a huge unmet medical need of aGvHD needs to be satisfied under the existing therapies.
Prior to the aGvHD trial, the proof of clinical efficacy and safety of AbGn-168H, a humanized monoclonal antibody, has been well demonstrated in a randomized, multicenter, double-blind, placebo-controlled phase II trial in patients with moderate-to-severe plaque psoriasis. Most recently, AbGenomics has also initiated an open-label, multi-center phase II study for psoriatic arthritis. The company is dedicated to bring forth this potential game-changing therapeutic candidate for the treatment of various inflammatory diseases.
About AbGenomics (www.abgenomics.com)
AbGenomics International Inc. (AbG) is an innovative, clinical-stage biopharmaceutical company developing targeted antibody therapeutics for the treatment of immune-mediated inflammatory diseases and cancers. Headquartered in San Francisco Bay Area, U.S., AbGenomics has subsidiaries in the Netherlands and in Taiwan. The lead candidate for anti-inflammatory therapy, Neihulizumab (AbGn-168H), is a therapeutic antibody with potential of long lasting drug-free remission and less risk concern for infections. In company’s oncology portfolio, the biosuperior antibody drug conjugate (ADC), featured on their superior efficacy and safety profiles, has proved to show a sustainable competitive advantage over our competitors. The Company’s strategy is to commercialize its novel products in collaboration with major pharmaceutical partners in order to maximize the opportunity for development and marketing of the Company’s compounds.
SOURCE: AbGenomics
Post Views: 36
